Thank you. It’s not easy to bring anyone reading my thoughts or let’s say my efforts in seriously breaking down; absolute basics of what makes CAPR another huge capital gain investment like Nvidia before Nvidia took off on their launching pad.
Just the fact over these last several trading days, has seen major market declines do impart with the Tariff Wars have begun. These are great times to acquire stocks well reduced in fair value and current PE levels. I always keep plenty of capital ready to invest in the markets who have tossed out everything (Baby out with the Bathwater) bringing in great returns if willing to let the Money Math set the course for high significant capital gains.
Let’s just look at $CAPR near-term, if I’m not mistaken, the majority of the analyst that are following Capricor have not changed their price targets. The analysts to date CAPR between the low $30-$77 dollars per share; leading to my reason of owning substantial shares, now hovering just under 85,750 and counting, because we added to this with the current price dipping in the $8 dollar range didn’t see the intuitional investors falling asleep at the wheel. Clearly if taking in my dollar cost averaging at $4.76 cents a share levels this investment as a long-term strategy seeking a Nvidia potential 2,750% capital gain.
If you read my articles on Penny.Stocks, I go to great lengths to do the same, as I did with this article. When I purchased Mesoblast ($MESO) in currently holding just under 54,650 shares. Making these buy and hold is always done by complex analysis of their potential to reach FDA approval’s. By purchasing over several years and keeping watch; once the Biotech has established themselves as holding a status of DERISKED; with much more upside than the negative downside, when new novel drug development is being introduced to the medical needs being addressed and significantly met. My dollar cost averaging in $MESO is $3.89 cents a share. The one other Biotech I have been buying and holding is Cytodyne $CYDY with accumulating near 650,400 shares with a dollar cost averaging of$.1975 cents per share. Read my latest article on Cytodyne and catch why they are actually much closer in establishing themselves as a DERISKED Biotech company severely undervalued by huge margins.
Do your do diligence on every single investment you make. If the Money Math doesn’t add up, you know better to move on.
KEEPING YOUR EYE ON THE TRUTH CAN BE A DIFFERENCE BETWEEN BEING IN $CAPR INSTEAD OF OUT OF A LONG POSITION.
President-elect Donald Trump has nominated Dr. Marty Makary, a surgeon and public policy researcher at Johns Hopkins University, to lead the U.S. Food and Drug Administration (FDA). Dr. Makary is known for his criticism of certain public health measures during the COVID-19 pandemic and has advocated for reducing bureaucratic obstacles within federal health agencies.
Dr. Makary’s approach to the FDA’s drug approval process emphasizes streamlining procedures to expedite the availability of treatments for serious conditions, such as Duchenne Muscular Dystrophy (DMD). He has expressed concerns about the agency’s “cozy relationship” with drug manufacturers and has criticized specific FDA decisions, including the approval of certain COVID-19 vaccines and Alzheimer’s treatments.
The FDA has recently approved several treatments for DMD, including:
• Elevidys (delandistrogene moxeparvovec): A gene therapy approved in June 2023 for pediatric patients aged 4 through 5 years with a confirmed mutation in the DMD gene.
• Duvyzat (givinostat): An oral medication approved in March 2024 for the treatment of DMD in patients six years and older, representing the first nonsteroidal drug approved for all genetic variants of DMD.
Dr. Makary’s potential leadership could influence the FDA’s approach to approving such treatments. While his intent to reduce bureaucratic delays may accelerate the availability of new therapies, his critical stance on certain FDA decisions suggests he may implement more stringent evaluation processes to ensure drug efficacy and safety.
In summary, Dr. Makary’s nomination indicates a potential shift in the FDA’s drug approval process, aiming to balance expedited access to treatments for diseases like DMD with rigorous scientific evaluation to maintain public trust and safety.
Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
How Science Meets A.I.
KEEPING YOUR EYE ON THE TRUTH CAN BE A DIFFERENCE BETWEEN BEING IN $CAPR INSTEAD OF OUT OF A LONG POSITION.
President-elect Donald Trump has nominated Dr. Marty Makary, a surgeon and public policy researcher at Johns Hopkins University, to lead the U.S. Food and Drug Administration (FDA). Dr. Makary is known for his criticism of certain public health measures during the COVID-19 pandemic and has advocated for reducing bureaucratic obstacles within federal health agencies.
Dr. Makary’s approach to the FDA’s drug approval process emphasizes streamlining procedures to expedite the availability of treatments for serious conditions, such as Duchenne Muscular Dystrophy (DMD). He has expressed concerns about the agency’s “cozy relationship” with drug manufacturers and has criticized specific FDA decisions, including the approval of certain COVID-19 vaccines and Alzheimer’s treatments.
The FDA has recently approved several treatments for DMD, including:
• Elevidys (delandistrogene moxeparvovec): A gene therapy approved in June 2023 for pediatric patients aged 4 through 5 years with a confirmed mutation in the DMD gene.
• Duvyzat (givinostat): An oral medication approved in March 2024 for the treatment of DMD in patients six years and older, representing the first nonsteroidal drug approved for all genetic variants of DMD.
Dr. Makary’s potential leadership could influence the FDA’s approach to approving such treatments. While his intent to reduce bureaucratic delays may accelerate the availability of new therapies, his critical stance on certain FDA decisions suggests he may implement more stringent evaluation processes to ensure drug efficacy and safety.
In summary, Dr. Makary’s nomination indicates a potential shift in the FDA’s drug approval process, aiming to balance expedited access to treatments for diseases like DMD with rigorous scientific evaluation to maintain public trust and safety.